Indoor Biotechnologies

Executive Summary

Indoor Biotechnologies (InBio), headquartered in Charlottesville, VA, has been a cornerstone in allergen research and diagnostics since 1988. The company provides highly purified allergens, ELISA/MARIA® test kits, and contract research services to support asthma, allergy, and immunology studies. Its clientele includes pharmaceutical companies, academic institutions, government agencies, and consumer product R&D teams, reflecting its broad utility in both basic research and product development. InBio's expertise lies in enabling accurate allergen detection and quantification, which is critical for developing therapies and diagnostic tools for allergic diseases. As the prevalence of allergies and asthma continues to rise globally, InBio is well-positioned to capitalize on growing demand for standardized allergen reagents and testing services. The company's long-standing reputation and technical proficiency offer a competitive edge, particularly as regulatory agencies emphasize the need for reliable allergen controls. While InBio is not a drug developer, its role as an essential supplier to the allergy research ecosystem makes it a stable, low-risk investment opportunity with steady growth potential. Upcoming catalysts include new product launches and strategic partnerships that could expand its market reach and revenue streams.

Upcoming Catalysts (preview)

• Q3 2026Launch of a next-generation allergen panel for multiplex testing70% success
• Q4 2026Strategic partnership with a major pharmaceutical company for immunotherapy development support50% success
• Q1 2027FDA clearance for a new MARIA-based diagnostic test kit40% success